Carna Biosciences, Inc.
Research Carna Biosciences, Inc. (4572.T) on Bullrun: market cap JPY 7.11B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4572.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 7.11B
- Financial periodFY2025
- RevenueJPY 579.06M
- Revenue growth-9.0%
- Net income-JPY 2.17B
- Free cash flow-JPY 2.17B
- Gross margin67.0%
Valuation Snapshot
latest market cap is JPY 7.11B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 579.06M | -JPY 2.17B | -JPY 2.17B | 67.0% | -113.62 | JPY 516.79M | JPY 714.49M | JPY 309.22M |
| FY2024 | JPY 636.24M | -JPY 2.18B | -JPY 1.39B | 73.2% | -121.64 | JPY 2.11B | JPY 61.34M | JPY 2.48B |
| FY2023 | JPY 1.63B | -JPY 1.15B | -JPY 1.69B | 89.2% | -68.62 | JPY 2.89B | JPY 182.97M | JPY 3.88B |
| FY2022 | JPY 1.39B | -JPY 1.35B | -JPY 834.39M | 87.6% | -99.1 | JPY 3.38B | JPY 300.39M | JPY 3.64B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 7.11B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Carna Biosciences, Inc.
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Carna Biosciences, Inc.'s market cap?
Carna Biosciences, Inc.'s market capitalization is JPY 7.11B.
What does Carna Biosciences, Inc. do?
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions.